U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Retinal exudate

MedGen UID:
116111
Concept ID:
C0240897
Finding
Synonym: Retinal exudates
SNOMED CT: Retinal exudates (39832008)
 
HPO: HP:0001147

Definition

Fluid which has escaped from retinal blood vessels with a high concentration of lipid, protein, and cellular debris with a typically bright, reflective, white or cream colored appearance on the surface of the retina. [from HPO]

Conditions with this feature

Exudative vitreoretinopathy 1
MedGen UID:
343561
Concept ID:
C1851402
Disease or Syndrome
Familial exudative vitreoretinopathy (FEVR) is an inherited disorder characterized by the incomplete development of the retinal vasculature. Its clinical appearance varies considerably, even within families, with severely affected patients often registered as blind during infancy, whereas mildly affected patients with few or no visual problems may have such a small area of avascularity in their peripheral retina that it is visible only by fluorescein angiography. It is believed that this peripheral avascularity is the primary anomaly in FEVR and results from defective retinal angiogenesis. The sight-threatening features of the FEVR phenotype are considered secondary to retinal avascularity and develop because of the resulting retinal ischemia; they include the development of hyperpermeable blood vessels, neovascularization, vitreoretinal traction, retinal folds, and retinal detachments (summary by Poulter et al., 2010). In 31 Chinese pedigrees clinically diagnosed with FEVR, Rao et al. (2017) analyzed 6 FEVR-associated genes and identified mutations in 12 of the probands, including 5 (16.1%) in LRP5, 3 (9.7%) in NDP, 2 (6.5%) in FZD4, and 1 (3.2%) in TSPAN12. In addition, a mutation in the KIF11 gene (148760) was identified in a patient who also exhibited microcephaly (MCLMR; 152950). The authors noted that their detection rate did not exceed 50%, suggesting that other FEVR-associated genes remained to be discovered. Genetic Heterogeneity of Familial Exudative Vitreoretinopathy Also see EVR2 (305390), caused by mutation in the NDP gene (300658) on chromosome Xp11; EVR3 (605750), mapped to 11p13-p12; EVR4 (601813), caused by mutations in the LRP5 gene (603506) on 11q13.4; EVR5 (613310), caused by mutation in the TSPAN12 gene (613138) on 7q31; EVR6 (616468), caused by mutation in the ZNF408 gene (616454) on 11p11; and EVR7 (617572), caused by mutation in the CTNNB1 gene (116806) on chromosome 3p22.
Exudative vitreoretinopathy 3
MedGen UID:
344184
Concept ID:
C1854002
Disease or Syndrome
Familial exudative vitreoretinopathy (FEVR) is an inherited disorder characterized by the incomplete development of the retinal vasculature. Its clinical appearance varies considerably, even within families, with severely affected patients often registered as blind during infancy, whereas mildly affected patients with few or no visual problems may have such a small area of avascularity in their peripheral retina that it is visible only by fluorescein angiography. It is believed that this peripheral avascularity is the primary anomaly in FEVR and results from defective retinal angiogenesis. The sight-threatening features of the FEVR phenotype are considered secondary to retinal avascularity and develop because of the resulting retinal ischemia; they include the development of hyperpermeable blood vessels, neovascularization, vitreoretinal traction, retinal folds, and retinal detachments (summary by Poulter et al., 2010). For a discussion of genetic heterogeneity of familial exudative vitreoretinopathy, see EVR1 (133780).
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations
MedGen UID:
348124
Concept ID:
C1860518
Disease or Syndrome
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a small-vessel disease that affects highly vascularized tissues including the retina, brain, liver, and kidneys. Age of onset is often between 35 and 50 years. The most common presenting finding is decreased visual acuity and/or visual field defects. Neurologic manifestations may include hemiparesis, facial weakness, aphasia, and hemianopsia. Migraines and seizures are less frequently described. Renal manifestations may include mild-to-moderate increase in serum creatinine and mild proteinuria; progression to end-stage renal disease (ESRD) is uncommon. Hepatic manifestations frequently include mildly elevated levels of alkaline phosphatase and gamma-glutamyltransferase (GGT). Less common findings include psychiatric disorders, hypertension, mild-to-moderate anemia, and Raynaud phenomenon.
Exudative vitreoretinopathy 4
MedGen UID:
356171
Concept ID:
C1866176
Disease or Syndrome
Familial exudative vitreoretinopathy (FEVR) is an inherited disorder characterized by the incomplete development of the retinal vasculature. Its clinical appearance varies considerably, even within families, with severely affected patients often registered as blind during infancy, whereas mildly affected patients with few or no visual problems may have such a small area of avascularity in their peripheral retina that it is visible only by fluorescein angiography. It is believed that this peripheral avascularity is the primary anomaly in FEVR and results from defective retinal angiogenesis. The sight-threatening features of the FEVR phenotype are considered secondary to retinal avascularity and develop because of the resulting retinal ischemia; they include the development of hyperpermeable blood vessels, neovascularization, vitreoretinal traction, retinal folds, and retinal detachments (summary by Poulter et al., 2010). For a discussion of genetic heterogeneity of familial exudative vitreoretinopathy, see EVR1 (133780).
Exudative vitreoretinopathy 5
MedGen UID:
412872
Concept ID:
C2750079
Disease or Syndrome
Familial exudative vitreoretinopathy is an inherited blinding disorder caused by defects in the development of retinal vasculature. There is extensive variation in disease severity among patients, even between members of the same family. Severely affected individuals often are registered as blind during infancy and can present with a phenotype resembling retinal dysplasia. Conversely, mildly affected individuals frequently have few or no visual problems and may have just a small area of avascularity in their peripheral retina, detectable only by fluorescein angiography (summary by Poulter et al., 2012). For a discussion of genetic heterogeneity of familial exudative vitreoretinopathy (FEVR), see EVR1 (133780).
Exudative vitreoretinopathy 6
MedGen UID:
902559
Concept ID:
C4225316
Disease or Syndrome
Familial exudative vitreoretinopathy is a hereditary disorder that can cause vision loss that worsens over time. This condition affects the retina, the specialized light-sensitive tissue that lines the back of the eye. In people with this disorder, blood vessels do not fully develop at the outer edges (periphery) of the retina, which reduces the blood supply to this tissue. This prolonged reduction in blood supply (chronic ischemia) causes continued damage to the retina and can lead to worsening of the condition. \n\nThe signs and symptoms of familial exudative vitreoretinopathy vary widely, even within the same family. In many affected individuals, the retinal abnormalities never cause any vision problems. Other people with this condition develop abnormal vessels that leak. This  causes chronic inflammation which, over time, can lead to fluid under the retina (exudate). A reduction in the retina's blood supply causes the retina to fold, tear, or separate from the back of the eye (retinal detachment). The resulting retinal damage can lead to vision loss and blindness. Other eye abnormalities are also possible, including eyes that do not look in the same direction (strabismus) and a visible whiteness (leukocoria) in the normally black pupil.\n\nSome people with familial exudative vitreoretinopathy also have a condition known as osteoporosis-pseudoglioma syndrome, which is characterized by reduced bone density. People with this condition have weakened bones and an increased risk of fractures.
Cerebroretinal microangiopathy with calcifications and cysts 3
MedGen UID:
1841133
Concept ID:
C5830497
Disease or Syndrome
Cerebroretinal microangiopathy with calcifications and cysts-3 (CRMCC3) is an autosomal recessive disorder characterized by intrauterine growth retardation, retinal exudates, intracranial calcifications, and leukoencephalopathy. Additional features may include global developmental delay and gastrointestinal ectasias. Telomeres may be elongated, but truncated shortened telomeres are present in some tissues (Takai et al., 2016). For a discussion of genetic heterogeneity of CRMCC, see CRMCC1 (612199).

Professional guidelines

PubMed

Doi A, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Uji A, Muraoka Y, Miyake M, Takahashi A, Wakazono T, Yamashiro K, Tsujikawa A
Am J Ophthalmol 2021 Sep;229:152-159. Epub 2021 Apr 8 doi: 10.1016/j.ajo.2021.02.034. PMID: 33838120

Recent clinical studies

Etiology

Hashimoto I, Takase H, Kase S, Iwasaki Y, Kobayashi D, Ohno-Matsui K
Retin Cases Brief Rep 2024 Jan 1;18(1):106-111. doi: 10.1097/ICB.0000000000001310. PMID: 36067444
Doi A, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Uji A, Muraoka Y, Miyake M, Takahashi A, Wakazono T, Yamashiro K, Tsujikawa A
Am J Ophthalmol 2021 Sep;229:152-159. Epub 2021 Apr 8 doi: 10.1016/j.ajo.2021.02.034. PMID: 33838120
Suzuki J, Goto H, Minoda H, Iwasaki T, Sakai J, Usui M
Ocul Immunol Inflamm 2006 Jun;14(3):165-70. doi: 10.1080/09273940600672198. PMID: 16766400
Yang CS, Tsai DC, Lee FL, Hsu WM
Ophthalmologica 2005 Nov-Dec;219(6):366-72. doi: 10.1159/000088380. PMID: 16286797
Atmaca LS
Graefes Arch Clin Exp Ophthalmol 1989;227(4):340-4. doi: 10.1007/BF02169409. PMID: 2777102

Diagnosis

Hashimoto I, Takase H, Kase S, Iwasaki Y, Kobayashi D, Ohno-Matsui K
Retin Cases Brief Rep 2024 Jan 1;18(1):106-111. doi: 10.1097/ICB.0000000000001310. PMID: 36067444
Miyata M, Ooto S, Hata M, Takahashi A, Tsujikawa A
Medicine (Baltimore) 2021 Oct 22;100(42):e27578. doi: 10.1097/MD.0000000000027578. PMID: 34678904Free PMC Article
Doi A, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Uji A, Muraoka Y, Miyake M, Takahashi A, Wakazono T, Yamashiro K, Tsujikawa A
Am J Ophthalmol 2021 Sep;229:152-159. Epub 2021 Apr 8 doi: 10.1016/j.ajo.2021.02.034. PMID: 33838120
Imani E, Pourreza HR
Comput Methods Programs Biomed 2016 Sep;133:195-205. Epub 2016 May 31 doi: 10.1016/j.cmpb.2016.05.016. PMID: 27393810
Davis JL, Nussenblatt RB, Bachman DM, Chan CC, Palestine AG
Am J Ophthalmol 1989 Jun 15;107(6):613-23. doi: 10.1016/0002-9394(89)90258-4. PMID: 2658616

Therapy

Miyata M, Ooto S, Hata M, Takahashi A, Tsujikawa A
Medicine (Baltimore) 2021 Oct 22;100(42):e27578. doi: 10.1097/MD.0000000000027578. PMID: 34678904Free PMC Article
Doi A, Miyata M, Ooto S, Tamura H, Ueda-Arakawa N, Uji A, Muraoka Y, Miyake M, Takahashi A, Wakazono T, Yamashiro K, Tsujikawa A
Am J Ophthalmol 2021 Sep;229:152-159. Epub 2021 Apr 8 doi: 10.1016/j.ajo.2021.02.034. PMID: 33838120
Song JH, Koreishi AF, Goldstein DA
Ocul Immunol Inflamm 2019;27(6):998-1009. Epub 2018 Jul 3 doi: 10.1080/09273948.2018.1485958. PMID: 29969330
Matsuyama K, Ogata N, Takahashi K, Matsumura M, Nishimura T
Graefes Arch Clin Exp Ophthalmol 2008 Jul;246(7):1065-7. Epub 2008 Apr 11 doi: 10.1007/s00417-008-0790-y. PMID: 18404274
Panton RW, Goldberg MF, Farber MD
Br J Ophthalmol 1990 Oct;74(10):595-600. doi: 10.1136/bjo.74.10.595. PMID: 2285682Free PMC Article

Prognosis

Miyata M, Ooto S, Hata M, Takahashi A, Tsujikawa A
Medicine (Baltimore) 2021 Oct 22;100(42):e27578. doi: 10.1097/MD.0000000000027578. PMID: 34678904Free PMC Article
Suzuki J, Goto H, Minoda H, Iwasaki T, Sakai J, Usui M
Ocul Immunol Inflamm 2006 Jun;14(3):165-70. doi: 10.1080/09273940600672198. PMID: 16766400
Yang CS, Tsai DC, Lee FL, Hsu WM
Ophthalmologica 2005 Nov-Dec;219(6):366-72. doi: 10.1159/000088380. PMID: 16286797
Atmaca LS
Graefes Arch Clin Exp Ophthalmol 1989;227(4):340-4. doi: 10.1007/BF02169409. PMID: 2777102

Clinical prediction guides

Miyata M, Ooto S, Hata M, Takahashi A, Tsujikawa A
Medicine (Baltimore) 2021 Oct 22;100(42):e27578. doi: 10.1097/MD.0000000000027578. PMID: 34678904Free PMC Article
Song JH, Koreishi AF, Goldstein DA
Ocul Immunol Inflamm 2019;27(6):998-1009. Epub 2018 Jul 3 doi: 10.1080/09273948.2018.1485958. PMID: 29969330
Suzuki J, Goto H, Minoda H, Iwasaki T, Sakai J, Usui M
Ocul Immunol Inflamm 2006 Jun;14(3):165-70. doi: 10.1080/09273940600672198. PMID: 16766400
Yang CS, Tsai DC, Lee FL, Hsu WM
Ophthalmologica 2005 Nov-Dec;219(6):366-72. doi: 10.1159/000088380. PMID: 16286797

Recent systematic reviews

Song JH, Koreishi AF, Goldstein DA
Ocul Immunol Inflamm 2019;27(6):998-1009. Epub 2018 Jul 3 doi: 10.1080/09273948.2018.1485958. PMID: 29969330

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...